Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients

• Published in: Lung cancer (Amsterdam, Netherlands) Netherlands), 2019-09, Vol.135, p.138-144
• Main Authors: Hu, Fang, Li, Changhui, Xu, Jianlin, Guo, Jindong, Shen, Yinchen, Nie, Wei, Zheng, Xiaoxuan, Wang, Lixin, Zhang, Hai, Han, Baohui, Zhang, Xueyan
• Format: Article
• Language: English
• Subjects: Bone oligometastases; Epidermal growth factor receptor mutation; Local consolidative therapy; Tyrosine-kinase inhibitors
• ISSN: 0169-5002; 1872-8332
• DOI: 10.1016/j.lungcan.2019.07.024

•The efficacy of LCT in bone oligometastatic lung adenocarcinoma is controversial.•This study provided real-world treatment outcomes in bone oligometastatic patients.•The current findings suggested that additional LCT could bring survival benefits.•LCT plus EGFR-TKIs could be a better therapeutic option in these patients. Whether epidermal growth factor receptor tyrosine-kinase inhibitors (EGFR-TKIs) plus local consolidative therapy (LCT) has survival benefit over EGFR-TKIs alone in lung adenocarcinoma patients with EGFR mutation and bone oligometastases remains controversial. We conducted a retrospective study to assess the effects of LCT in lung adenocarcinoma patients with bone oligometastases and EGFR mutation. The primary endpoint was overall survival (OS); the secondary endpoints was progression-free survival (PFS). A total of 127 lung adenocarcinoma patients with EGFR mutation and bone oligometastases were assessed, including 65 patients received EGFR-TKIs alone (monotherapy group) and 62 patients received EGFR-TKIs plus local consolidative therapy (LCT) (combination group). Addition of LCT was associated with significantly longer OS (36.3 vs. 21.0 months, P = 0.01; hazard ratio [HR] = 0.537, 95% confidence interval [CI]: 0.360-0.801, p = 0.01) and PFS (14.0 vs. 8.1 months, P = 0.01; HR = 0.613, 95%CI: 0.427-0.879, p = 0.01) in the whole cohort. In lung adenocarcinoma patients with EGFR-mutation and bone oligometastases, LCT plus EGFR-TKIs therapy is associated with significantly longer OS and PFS compared with EGFR-TKIs therapy alone, indicating that LCT plus EGFR-TKIs therapy might be a better therapeutic option for this patient population.